Shenzhen Bioeasy Biotechnology Co. Ltd. - Asset Resilience Ratio
Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) has an Asset Resilience Ratio of 12.61% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 300942 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Shenzhen Bioeasy Biotechnology Co. Ltd.'s Asset Resilience Ratio has changed over time. See Shenzhen Bioeasy Biotechnology Co. Ltd. net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Shenzhen Bioeasy Biotechnology Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300942 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥187.64 Million | 12.61% |
| Total Liquid Assets | CN¥187.64 Million | 12.61% |
Asset Resilience Insights
- Moderate Liquidity: Shenzhen Bioeasy Biotechnology Co. Ltd. has 12.61% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Shenzhen Bioeasy Biotechnology Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Shenzhen Bioeasy Biotechnology Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Shenzhen Bioeasy Biotechnology Co. Ltd. (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Shenzhen Bioeasy Biotechnology Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 15.43% | CN¥235.30 Million ≈ $34.43 Million |
CN¥1.52 Billion ≈ $223.09 Million |
-5.35pp |
| 2024-12-31 | 20.79% | CN¥302.92 Million ≈ $44.33 Million |
CN¥1.46 Billion ≈ $213.23 Million |
+11.94pp |
| 2023-12-31 | 8.85% | CN¥120.03 Million ≈ $17.56 Million |
CN¥1.36 Billion ≈ $198.48 Million |
-20.67pp |
| 2021-12-31 | 29.52% | CN¥340.21 Million ≈ $49.78 Million |
CN¥1.15 Billion ≈ $168.65 Million |
+26.29pp |
| 2019-12-31 | 3.23% | CN¥20.00 Million ≈ $2.93 Million |
CN¥619.67 Million ≈ $90.68 Million |
-- |
About Shenzhen Bioeasy Biotechnology Co. Ltd.
Shenzhen Bioeasy Biotechnology Co., Ltd., together with its subsidiaries, provides rapid food testing reagents and instruments in China and internationally. The company offers test kits, including veterinary, melamine, mycotoxin, pesticide, adulteration, ATP, vitamin, and others; equipment, such as incubator, reader, suitcase lab, automatic pressers, and others; and materials comprising pretreatm… Read more